Abstract
Melanoma is the most aggressive form of skin cancer and advantages stages are inevitably resistant to conventional therapeutic agents. In particular, the inability of undergo apoptosis in response to chemotherapy and other external stimuli poses a selective advantage for tumor progression, metastasis formation as well as resistance to therapy in melanoma. Herein, we will review the discovery of MDR transporters and the apoptotic mechanisms used by melanoma cells. Furthermore, the novel strategies to overcome tumor chemoresistance will also discuss. In particular, we will review the cancer stem cell hypothesis and how the failure of MDR reversal agents might increase the therapeutic index of substrate antineoplastic agents.
Keywords: multi-drug resistance (MDR) Transporter, dacarbazine, ATP binding cassette (ABC) transporters, apoptosis, Chemoresistance
Current Medicinal Chemistry
Title: Drug Resistance in Melanoma: New Perspectives
Volume: 14 Issue: 4
Author(s): Caterina A.M. La Porta
Affiliation:
- Department of Biomolecular Science and Biotechnology, University of Milan, Italy.,Italy
Keywords: multi-drug resistance (MDR) Transporter, dacarbazine, ATP binding cassette (ABC) transporters, apoptosis, Chemoresistance
Abstract: Melanoma is the most aggressive form of skin cancer and advantages stages are inevitably resistant to conventional therapeutic agents. In particular, the inability of undergo apoptosis in response to chemotherapy and other external stimuli poses a selective advantage for tumor progression, metastasis formation as well as resistance to therapy in melanoma. Herein, we will review the discovery of MDR transporters and the apoptotic mechanisms used by melanoma cells. Furthermore, the novel strategies to overcome tumor chemoresistance will also discuss. In particular, we will review the cancer stem cell hypothesis and how the failure of MDR reversal agents might increase the therapeutic index of substrate antineoplastic agents.
Export Options
About this article
Cite this article as:
Caterina A.M. La Porta , Drug Resistance in Melanoma: New Perspectives, Current Medicinal Chemistry 2007; 14(4) . https://dx.doi.org/10.2174/092986707779941078
DOI https://dx.doi.org/10.2174/092986707779941078 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Therapeutic Potential of ADAM15
Current Pharmaceutical Design Anticancer Evaluation of 3,4,5,4'-trans-tetramethoxystilbene (DMU-212) and Its Analogs Against an Extensive Panel of Human Tumor Cell Lines
Letters in Drug Design & Discovery Editorial: [Hot Topic: Inflammation and Cancer: New Targets and Novel Therapeutic Approach]
Current Pharmaceutical Design Ribozyme- and Deoxyribozyme-Strategies for Medical Applications
Current Drug Targets Antimicrobial Peptides: Mediators of Innate Immunity as Templates for the Development of Novel Anti-Infective and Immune Therapeutics
Current Pharmaceutical Design Immunotherapy Approaches in Cancer Treatment
Current Pharmaceutical Biotechnology ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design Phenolic Compounds as Nutraceuticals or Functional Food Ingredients
Current Pharmaceutical Design Novel (S)-(-)- and R-(+)-seco-iso-cyclopropylfurano[e]indoline-5,6,7- trimethoxyindole-2-carboxamide (iso-CFI) Analogs of Duocarmycin C2: Synthesis and Biological Evaluation
Medicinal Chemistry Redox-inactive Analogue of Tocotrienol as a Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Proteins in Microglial Activation - Inputs and Outputs by Subsets
Current Protein & Peptide Science Current Targets for Anticancer Drug Discovery
Current Drug Targets Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics ADAM9 as a Potential Target Molecule in Cancer
Current Pharmaceutical Design Molecular Diagnosis in Autoimmune Skin Blistering Conditions
Current Molecular Medicine The Prolyl-Aminodipeptidases and their Inhibitors as Therapeutic Targets for Fibrogenic Disorders
Mini-Reviews in Medicinal Chemistry Therapeutic Targeting of Chemokines with Monoclonal Antibodies
Current Immunology Reviews (Discontinued) Do We have the Evidence to Repurpose Levamisole for Treatment of COVID 19?
Current Drug Therapy RING Finger E3 Ubiquitin Ligases: Structure and Drug Discovery
Current Pharmaceutical Design Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules
Current Medicinal Chemistry